Cytoreductive surgery combined with HIPEC in newly diagnosed and recurrent ovarian cancer

Objective: Perioperative intraperitoneal chemotherapy after cytoreductive surgery is used in ovarian cancer treatment. The purpose of the study is the evaluation of the effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as upfront treatment in advanced ovarian cancer. Materials and Methods: Prospective observational study of 166 women that underwent 189 cytoreductive operations for advanced ovarian cancer and in 55 of them HIPEC was used as upfront treatment. Clinical indicators were correlated to morbidity, hospital mortality, survival, and recurrences. Results: HIPEC as upfront treatment was found to be related to recurrence (p = 0.001) but not to overall survival. The prognostic variables of survival were the performance status, the completeness of cytoreduction, and the use of HIPEC (p < 0.001). The prognostic variables of recurrence were the degree of differentiation, and systemic chemotherapy (p = 0.05). Conclusion: HIPEC as upfront treatment after cytoreductive surgery may be another promising treatment strategy in patients with epithelial ovarian cancer. Prospective randomized trials are required.

Cytoreductive surgery; Peritoneal carcinomatosis; Ovarian cancer; HIPEC

[1] Randall T.C., Rubin S.C.: “Cytoreductive surgery for ovarian cancer”. Surg. Clin. N. Am. 2001, 81, 871.

[2] Cannistra S.A.: “Cancer of the ovary”. N. Engl. J. Med., 2004, 351, 2519.

[3] Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J.: “Cancer Statistics 2009”, CA. Cancer J. Clin., 2009, 59, 225.

[4] Chua T.C., Moran B.J., Sugarbaker P.H., Levine E. A., Glehen O., Gilly F.N., et al.: “Early and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy”. J. Clin. Oncol., 2012, 30, 2449.

[5] Yan T.D., Deraco M., Baratti D., Kusamura S., Elias D., Glehen O., et al.: “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience”. J. Clin. Oncol., 2009, 27, 6237.

[6] Glehen O., Gilly F.N., Boutitie F., Bereder J.M., Quenet F., Sideris L., et al.: “Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy”. Cancer, 2010, 116, 5608.

[7] Tentes A.A., Kakolyris S., Kyziridis D., Karamveri C.: “Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer”. J. Oncol., 2012, 2012, Article ID 358341, doi:10.1155/2012/358341.

[8] Di Giorgio A., Naticchioni E., Biacchi D., Sibio S., Accarpio F., Rocco M., et al.: “Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer”. Cancer, 2008, 113, 315.

[9] Raspagliesi F., Kusamura S., Campos Torres J. C., de Souza G. A., Ditto A., Zanaboni F., et al.: “Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan”. EJSO, 2006, 32, 671.

[10] Cotte E., Glehen O., Mohamed F., Lamy F., Falandry C., Golfier F., Gilly F.N.: “Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer”. World J. Surg., 2007, 31, 1813.

[11] Gonzalez-Bayon L., Steiner M.A., Vasquez Jimenez W., Asencio J. M., Alvarez de Sierra P., Atahualpa Arenas F., et al.: “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?” EJSO, 2013, 39, 460.

[12] Cowan R.A., O’Cearbhaill R.E., Zivanovic O., Chi D.S.: ”Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) Clinical trials in Ovarian Cancer”. Int. J. Hyperth., 2017, 16, 1.

[13] Tentes A.A., Tripsiannis G., Markakidis S. K., Karanikiotis Ch., Tzegas G., Georgiadis G., Avgidou K.: “Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer”. EJSO, 2003, 29, 69.

[14] Sugarbaker P.H.: In: Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery: manual for physicians and nurses, 3rd ed. Grand Rapids, MI: Ludann Co., 1998

[15] Sugarbaker P.H.: “Peritonectomy procedures”. Ann Surg., 1995, 221, 29.

[16] Griffith C.T.: “Surgical resections of tumor bulk in the primary treatment of ovarian carcinoma”. NCI Monogr., 1975, 42, 101.

[17] Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al.: “The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma”. Am. J. Obstet. Gynecol., 1994, 170, 974.

[18] Eisenkop S.M., Friedman R. L., Wang H. J.: “Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study”. Gynecol. Oncol., 1998, 69, 103.

[19] Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F. J.: “Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis”. J. Clin. Oncol., 2002, 20, 1248.

[20] Jacquet P., Sugarbaker P. H.: “Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis”. In: P. H. Sugarbaker (ed). Peritoneal Carcinomatosis: Principles of Management. Boston: Kluwer Academic Publishers, 1996, 359.

[21] Yong Z.Z., Tan G.H., Wong J.F., Lim C., Soo K. C., Teo M.C.: “Unresectability during open surgical exploration in planned cytoreductive surgery and hyperthermic intraperitoneal chemotherapy”. Int. J. Hyperth., 2016, 32, 889.

[22] Stamou K.M., Karakozis S., Sugarbaker P.H.: “Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous carcinomatosis from non-gynecologic cancer”. J. Surg. Oncol., 2003, 83, 197.

[23] Piso P., Slowik P., Popp F., Dahlke M.H., Glockzin G., Schlitt H.J.:“Safety of gastric resections during cytoreductive surgery and hyperthermic intrparitoneal chemotherapy for peritoneal carcinomatosis”. Ann. Surg. Oncol, 2009, 16, 2188-2194.

[24] Cascales Campos P.: “Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer”. EJSO, 2014, 40, 970.

[25] Kirmani S., Braly P. S., McClay E. F., Saltzstein S. L., Plaxe S. C., Kim S., et al.: “A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer”. Gynecol. Oncol., 1994, 54, 338.

[26] Alberts D.S., Liu P.Y., Hannigan E.V., O’ Toole R., Williams S.D., Young J.A., et al.: “Intraperitoneal cis-platin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer”. N. Engl. J. Med., 1996, 335, 1950..

[27] Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al.: “Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin fol- lowed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group”. J. Clin. Oncol., 2001, 19, 1001.

[28] Polyzos A., Tsavaris N., Kosmas C., Giannikos L., Katsikas N., Karatzas G., et al.: “A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer”. Oncology, 1999, 56, 291.

[30] Armstrong D.K., Bundy B., Wenzel L., Huang H. Q., Baergen R., Lele S., et al.: “Intraperitoneal cisplatin and paclitaxel in ovarian cancer”. N. Engl. J. Med., 2006, 354, 34.

[31] Bakrin N., Bereder J.M., Decullier E., Classe J.M., Msika S., Lorimier G., et al.: “Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients”. EJSO, 2013, 39, 1435.

[32] Look M., Chang D., Sugarbaker P.H.: “Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum”. Int. J. Gynecol. Cancer, 2004, 14, 35.